Predictive value of plasma haematocrit level in early diagnosis of pre-eclampsia

F. Golboni, S. Heydarpour, Z. Taghizadeh and A. Kazemnezhad

ABSTRACT While pre-eclampsia is the most common complication of pregnancy, a definitive screening test for early diagnosis is still elusive. In this study, haematocrit value was assessed as a screening test for pre-eclampsia in 660 women at 24–28 weeks of pregnancy attending a hospital in Tehran, Islamic Republic of Iran. Mean haematocrit values were significantly higher in pre-eclamptic than non-pre-eclamptic women: 37.7% (SD 2.0%) and 35.9% (SD 1.7%) respectively. The receiver operating characteristics curve showed that the most appropriate cut-off point for the haematocrit test in this sample of women was 38%; at this value the sensitivity was 58.6% and specificity was 88.9%; positive and negative predictive values were 33.7% and 95.7% respectively. The haematocrit, done as a routine screening test for anaemia at 24–28 weeks of pregnancy, may also be useful as a screening test for early diagnosis of pre-eclampsia.

1Department of Nursing Midwifery, Azad University, Sanandaj, Islamic Republic of Iran.
2Department of Nursing Midwifery, Kermanshah University of Medical Sciences, Kermanshah, Islamic Republic of Iran (Correspondence to S. Heydarpour: susan_haidarpor@yahoo.com).
3Department of Nursing Midwifery, Tehran University of Medical Sciences, Tehran, Islamic Republic of Iran.
4Department of Biostatistics, Tarbiat Modares University, Tehran, Islamic Republic of Iran.

Received: 10/08/09; accepted: 10/03/10
Introduction

Pre-eclampsia is the most common complication of pregnancy and, together with bleeding and infection, is one of the 3 main causes of death in mothers. It has been notified as a global health problem of women by the World Health Organization (WHO) [1,2]. Pre-eclampsia is a pregnancy-specific syndrome of unknown aetiology and diagnosed by systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg and proteinuria ≥300 mg/24h or dipstick 1+ after 20 weeks of pregnancy. Despite proper care during pregnancy and delivery, pre-eclampsia is still a major health threat, even in developed countries [3,4].

The prevalence of this disease in the world has been estimated at 5%–7% and in the Islamic Republic of Iran in Tehran at 6.5% [4–6]. A reliable criterion for early diagnosis of pre-eclampsia does not exist. Many clinical, biophysical and biochemical tests exist for the diagnosis of high-risk women, but the results of studies indicate they had little predictive value in early diagnosis. Furthermore, some of these screening tests are expensive and invasive [3,6–8]. Some research has indicated that haemodynamic changes in normal pregnancy, such as the increase of maternal plasma volume in the second trimester, do not occur in pre-eclampsia. This may, therefore, be an indicator for pre-eclampsia in future weeks [1,3,4,9,10]. Due to vasospasm and absence of hypervolemia in these patients the haematocrit value may increase [1,9,11]. In some studies serum haematocrit has been reported as an early diagnostic test for pre-eclampsia [1,10,12].

This study aimed to determine the predictive value of maternal haematocrit value at 24–28 weeks of pregnancy in the early diagnosis of pre-eclampsia. Maternal haematocrit is measured routinely in our hospital in the Islamic Republic of Iran for the diagnosis of anaemia at this stage of pregnancy and if the predictive value of this test is appropriate it may be recommended as a screening test for pre-eclampsia.

Methods

Sample

Sampling and follow-up of cases took 8 months from February 2006 to September 2007. The sample was selected from pregnant women attending the prenatal care clinic at Maryam Hospital in Tehran, Islamic Republic of Iran. Women with underlying diabetes, chronic hypertension, symptomatic infectious disease, renal disease, pulmonary disease, rheumatologic disease or thyroid disease were excluded from the study. Women with multiple pregnancies, antiphospholipid syndrome, anaemia, polycythaemia, body mass index (BMI) ≥30 kg/m² and history of recurrent pregnancy loss were also excluded.

The sample size was estimated with a 95% level of significance and $P < 0.05$ and assuming a positive predictive value of the test of 30%–40%, as reported in various studies. Thus 323 cases were estimated to be required. Taking into account possible losses, sample size was increased to 330 per category (330 women with 24–26 weeks gestational age and 330 with 27–28 weeks gestational age). Thus over the study period 660 pregnant women with a fetus at gestational age 24–28 weeks were enrolled. All gave informed consent for participation in the study. Three months after starting the sampling 52 women dropped out because of non-attendance at the clinic or refusal to participate and resampling was continued until the sample of 660 was completed. All women were taking regular ferrous sulfate supplements. Gestational age was estimated from the last menstrual period and confirmed by sonography in the first trimester of pregnancy.

Data collection

All the women were interviewed to record demographic data (age, marital status education, employment) and information about number of pregnancies, history of labour, history of abortion, history of pre-eclampsia and BMI in the first trimester of pregnancy.

Blood pressure was measured using a stethoscope and sphygmomanometer. Pre-eclampsia was defined as blood pressure ≥140/90 mmHg or greater obtained on 2 consecutive measurements 6 h apart, with proteinuria ≥+1 on 2 random urine samples or urine total protein >300 mg in 24 h. All measurements were done on one of 2 identical sphygmomanometers, whose accuracy was determined by the medical engineer of Maryam hospital.

Blood and urine samples were taken for routine screening tests. Haematocrit was measured once in each woman by centrifugation (Sysmex). The reliability of the centrifuge was checked by calibration daily in the hospital laboratory. Other tests, including measurements of platelet count, prothrombin time, partial thromboplastin time, serum urate and diagnostic parameters of liver and kidney function, were done to diagnose pre-eclampsia.

All women were followed-up for the remainder of their pregnancy for the occurrence of pre-eclampsia.

Analysis

For classifying and summarizing data, descriptive statistics were used. For the comparison of haematocrit results at 24–28 weeks in women with and without pre-eclampsia, the chi-squared test was used. The sensitivity and specificity of the haematocrit test were assessed using standard equations. For determining an appropriate cut-off point for the test, a receiver operating characteristic (ROC) curve was used. SPSS software, version 15, was used for analysis. $P$-values <0.05 were considered significant.

Results

The majority (91.7%) of the subjects were aged 19–35 years old. Their
mean age was 25.7 (SD 4.9) years. Most women (66.7%) had secondary education, 98.5% were married once and 91.5% were housewives. Pregnancy history showed that 462 (70.0%) of women were primigravidas, 73.9% had no history of delivery and 93.3% had no history of abortion. In the 198 multi-gravidas, 93.4% had no a history of pre-eclampsia in previous pregnancies. BMI was normal (19.8–26 kg/m²) in two-thirds (65.5%) of the women.

Of the 660 pregnant women, 58 (8.8%) had a diagnosis of pre-eclampsia and 602 had no signs of pre-eclampsia. The mean haematocrit values were significantly higher in pre-eclamptic than non-pre-eclamptic women: 37.7% (SD 2.0%) and 35.9% (SD 1.7%) respectively (chi-squared $P < 0.001$).

The ROC curve of sensitivity and specificity of the test showed that the optimal cut-off point for the haematocrit test in this sample of women at 24–28 weeks of pregnancy was 38% (Figure 1). Using this haematocrit cut-off 65.8% of women with a diagnosis of pre-eclampsia had a haematocrit above the cut-off compared with 11.1% of women without pre-eclampsia (Table 1). The difference between the 2 groups was statistically significant ($\chi^2 = 92.05, P < 0.001$). The sensitivity of the test using the 38% cut-off was 58.6% and specificity was 88.9% (Table 1). Positive predictive value was 33.7% and negative predictive value of the test was 95.7%.

![Figure 1](image-url)  
**Figure 1** Receiver operating characteristics curve showing optimal cut-off point for haematocrit value in early diagnosis of pre-eclampsia in women at 24–28 weeks of pregnancy

### Discussion

The pathogenesis of pre-eclampsia has not been well understood. In fact, the phenomenon may be silent from some time (2–3 months) before hypertension is expressed and the diagnosis of pre-eclampsia can be made [13]. Some evidences suggests that plasma volume in pre-eclampsia is lower than normal. Decreased plasma volume induces high haemoglobin concentration that leads to decreased placenta circulation that plays a pathogenic role in the development of pre-eclampsia [14].

Mello et al. assessed biochemical patterns in the early diagnosis of pre-eclampsia. They showed that the sensitivity of the haematocrit test in early diagnosis of pre-eclampsia was 63% and its specificity was 90%. Its positive predictive value was 36% and the negative predictive value of the test was 92% [15]. Their results are in accordance with ours. In Mello’s research, the haematocrit was measured every 4 weeks from the 8th week of pregnancy and the results were compared between the

---

**Table 1** Proportion of women at 24–28 weeks of pregnancy with raised haematocrit values among those with and without a diagnosis of pre-eclampsia

<table>
<thead>
<tr>
<th>Haematocrit (%)</th>
<th>Total</th>
<th>Pre-eclampsia</th>
<th>No</th>
<th>Statistics</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No.</td>
<td>%</td>
<td>No.</td>
<td>%</td>
</tr>
<tr>
<td>≥ 38</td>
<td>101</td>
<td>34</td>
<td>67</td>
<td>11.1</td>
</tr>
<tr>
<td>&lt; 38</td>
<td>559</td>
<td>24</td>
<td>535</td>
<td>98.8</td>
</tr>
<tr>
<td>Total</td>
<td>660</td>
<td>58</td>
<td>602</td>
<td>100.0</td>
</tr>
</tbody>
</table>
2nd and 3rd trimesters. Mello’s methods were different from ours because we measured the haematocrit only at 24–28 weeks of pregnancy. Our results showed that it may be possible to get the same predictive value by measuring haematocrit only once.

Our results are also in accordance with those of Hilman et al., who assessed the relationship between haemoglobin and haematocrit value in pregnancy outcome. The results of that cohort study showed that high haemoglobin and haematocrit values in the 2nd trimester have a relationship with pre-eclampsia in the following weeks [16]. They studied the relationship between haemoglobin and haematocrit value in the 1st and 3rd trimester and development of pre-eclampsia [14]. Another study in our country showed that the haematocrit value was significantly higher in pre-eclamptic women [17]. Other studies in other countries also found a relationship between an increased haematocrit and pre-eclampsia [18–21]. Other studies have shown varying results, however. In Sibai’s study the haematocrit was reported as only a weak test for the diagnosis of pre-eclampsia. The sensitivity of the haematocrit in early diagnosis of pre-eclampsia in their study was 20%, specificity was 42%, positive predictive value was 6% and negative predictive value was 50% [22]. In complete contrast, Sherbiny et al. reported no significant difference in haemoglobin concentration and haematocrit value between pregnant women with pre-eclampsia (mild and severe pre-eclampsia) and a normotensive matched control group [23].

**Conclusion**

Haematocrit, which is routinely done as a screening test for anaemia in 24–28 weeks of pregnancy, may be useful as a screening test for early diagnosis of pre-eclampsia in health centres. Women with haematocrit above the cut-off of 38% should be monitored carefully for the signs of pre-eclampsia.

References

17. Ensafgo M. [Relationship between hemoglobin and hematocrit with outcome of pregnancy in pregnant women referring to Shariati hospital]. [MSc thesis]. Department of Obstetrics and Gynecology, Tehran, Medical Sciences Faculty, Tehran University of Medical Sciences, 1998 [in Farsi].


**WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia**

Hypertensive disorders of pregnancy are an important cause of severe morbidity, long-term disability and death among both mothers and their babies. Among the hypertensive disorders that complicate pregnancy, pre-eclampsia and eclampsia stand out as major causes of maternal and perinatal mortality and morbidity.

The majority of deaths due to pre-eclampsia and eclampsia are avoidable through the provision of timely and effective care to the women presenting with these complications. Optimizing health care to prevent and treat women with hypertensive disorders is a necessary step towards achieving the Millennium Development Goals.

WHO has developed the above-mentioned evidence-informed recommendations with a view to promoting the best possible clinical practices for the management of pre-eclampsia and eclampsia. The final recommendations were formulated and approved by an international group of experts who participated in the WHO Technical Consultation on the Prevention and Treatment of Pre-eclampsia and Eclampsia, held in Geneva, Switzerland, on 7–8 April 2011. The recommendations are available at: http://www.who.int/reproductivehealth/publications/maternal_perinatal_health/9789241548335/en/